Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute pharmaceutical poisoning as a cause of seizure events: a database analysis (2011-2023).

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Diagnosing idiosyncratic drug-induced liver injury: lessons from monocyte-derived hepatocyte-like cells.

Expert opinion on drug metabolism & toxicology·2026
Same author

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

EBioMedicine·2026
Same author

The waiting room of uncertainty: digital patient support for potentially bad news-a scoping review.

Frontiers in digital health·2025
Same author

Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients.

Oncology·2025
Same author

The Role of Folate Receptor α Autoantibodies in Folate Deficiency, Disease Severity, and Treatment Response in Adolescents with Major Depressive Disorder.

The Journal of nutrition·2025

Related Experiment Video

Updated: May 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

[Thrombocyte aggregation inhibitors: what are the risks?].

Ivanka Curkovic1, Marco Egbring, Gerd A Kullak-Ublick

  • 1Klinik für Klinische Pharmakologie und Toxikologie, Universitätsspital Zürich.

Praxis
|October 4, 2013
PubMed
Summary

Newer platelet inhibitors like prasugrel and ticagrelor offer improved efficacy over clopidogrel but may increase bleeding risk. Patient-specific factors and drug interactions require careful management for optimal antiplatelet therapy.

Keywords:
BlutungsrisikoPrasugrelThrombozytenaggregationshemmerTicagreloradverse drug eventsantiagrégants plaquettairesbleeding riskeffets secondairesplatelet inhibitorsprasugrelrisque d'hémorragieticagrelorunerwünschte Wirkungen

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Related Experiment Videos

Last Updated: May 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelet inhibitor therapy is crucial for preventing ischemic events.
  • Common risks include bleeding, drug interactions, and therapeutic failure.
  • Clopidogrel, a common agent, has significant non-response rates, partly due to genetic factors.

Purpose of the Study:

  • To compare the efficacy and safety of newer potent platelet inhibitors (prasugrel, ticagrelor) with clopidogrel.
  • To highlight the risks and management strategies associated with these therapies.

Main Methods:

  • Review of current evidence on platelet inhibitor therapies.
  • Comparison of clinical outcomes and adverse events.
  • Analysis of factors influencing therapeutic response and safety.

Main Results:

  • Prasugrel and ticagrelor are more potent than clopidogrel, reducing ischemic events but potentially increasing bleeding.
  • Genetic polymorphisms do not currently appear to affect ticagrelor or prasugrel efficacy.
  • Specific patient populations (e.g., elderly, low weight) and drug combinations require dose adjustments or are contraindicated.

Conclusions:

  • Potent antiplatelet agents offer benefits but necessitate careful risk management.
  • Individualized therapy is essential to minimize adverse events and optimize outcomes.
  • Understanding drug-drug interactions and patient-specific factors is key for safe and effective treatment.